2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
J

2020 ASCO Highlights on Stage 3 EGFR+ NSCLC: Should Osimertinib Be Considered for Patients With EGFR Exon 21 Mutation in Adjuvant Setting?

By 2020 ASCO Virtual Direct™ Highlights FEATURING John Vu
By 2020 ASCO Virtual Direct™ Highlights FEATURING John Vu
0 views
September 28, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
Lung
06:34
2020 ASCO Virtual Direct™ Highlights

FDA Approved Pralsetinib (BLU-667) in RET+ mNSCLC: ARROW Trial Overv…

Feat. M. Shafique
05:39
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on ctDNA: Can We Use ctDNA as a Marker of MRD Follo…

Feat. M. Dietrich
15:28
2020 ASCO Virtual Direct™ Highlights

Update on ctDNA in NSCLC: Does ctDNA Predict Post-Therapy PFS & …

Feat. M. Dietrich
16:48
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Stage 3 EGFR+ NSCLC: Should Osimertinib Be C…

Feat. J. Vu
15:13
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on IO in ES-SCLC: Should You Recommend 1L IO+EP Co…

Feat. J. Vu
13:19
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on 1L mNSCLC: Nivo + Ipi + 2 Cycles Chemo vs. 4 Cyc…

Feat. M. Shafique
11:33
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on mNSCLC: Will the Efficacy of T-DXd in HER2+ …

Feat. M. Shafique